VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth.
暂无分享,去创建一个
Joo‐Hang Kim | C. Yun | Eok-Cheon Kim | N. Kim | J. Yoo | Young-Guen Kwon | H. Choi
[1] Yu Seong Lee,et al. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect , 2006, Gene Therapy.
[2] C. Contag,et al. Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[3] F. Motoi,et al. Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region , 2006, Cancer Gene Therapy.
[4] Francesco Niola,et al. Vector-based RNA interference against vascular endothelial growth factor-A significantly limits vascularization and growth of prostate cancer in vivo , 2005, Cancer Gene Therapy.
[5] E. Scholar,et al. Role of Tyrosine Kinase Inhibitors in Cancer Therapy , 2005, Journal of Pharmacology and Experimental Therapeutics.
[6] G. Soff,et al. Update on angiogenesis inhibitors. , 2005, Current opinion in oncology.
[7] J. Harmey,et al. Angiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF) , 2005, Journal of cellular and molecular medicine.
[8] B. Rouse,et al. Blocking mouse MMP-9 production in tumor cells and mouse cornea by short hairpin (sh) RNA encoding plasmids. , 2005, Oligonucleotides.
[9] Bart Landuyt,et al. Vascular Endothelial Growth Factor and Angiogenesis , 2004, Pharmacological Reviews.
[10] K. Strebhardt,et al. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. , 2004, Journal of the National Cancer Institute.
[11] Y. Yuzawa,et al. A Small Interfering RNA Targeting Vascular Endothelial Growth Factor as Cancer Therapeutics , 2004, Cancer Research.
[12] Y. Gho,et al. Capsaicin Inhibits in Vitro and in Vivo Angiogenesis , 2004, Cancer Research.
[13] C. Bucana,et al. E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model. , 2003, Molecular cancer therapeutics.
[14] L. Benjamin,et al. Angiogenesis: Tumorigenesis and the angiogenic switch , 2003, Nature Reviews Cancer.
[15] I. Kuhn,et al. Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes , 2002, Cancer Gene Therapy.
[16] R. Bernards,et al. A System for Stable Expression of Short Interfering RNAs in Mammalian Cells , 2002, Science.
[17] D. Kirn. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of Phase I and II trials , 2001, Expert opinion on biological therapy.
[18] I. Ganly,et al. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status , 2000, Gene Therapy.
[19] Stanley J. Wiegand,et al. Vascular-specific growth factors and blood vessel formation , 2000, Nature.
[20] I. Tannock,et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.
[21] M. Hung,et al. Inhibition of angiogenesis and induction of apoptosis are involved in E1A-mediated bystander effect and tumor suppression. , 2000, Cancer research.
[22] M. Gulley,et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] Y. G. Kwon,et al. Sphingosine 1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. , 1999, Biochemical and biophysical research communications.
[24] M. Mehtali,et al. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli , 1996, Journal of virology.
[25] Bing Li,et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.
[26] R. Nicosia,et al. Modulation of microvascular growth and morphogenesis by reconstituted basement membrane gel in three-dimensional cultures of rat aorta: A comparative study of angiogenesis in Matrigel, collagen, fibrin, and plasma clot , 1990, In Vitro Cellular & Developmental Biology.
[27] E. Jaffe,et al. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.
[28] Hoguen Kim,et al. ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis , 2005, Cancer Gene Therapy.
[29] Martin Vanderlaan,et al. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro , 2004, Angiogenesis.
[30] D. Gray,et al. The reduction of Raf-1 protein by phosphorothioate ODNs and siRNAs targeted to the same two mRNA sequences. , 2003, Oligonucleotides.
[31] H. Pehamberger,et al. Small interfering RNA targeting bcl-2 sensitizes malignant melanoma. , 2003, Oligonucleotides.
[32] D. Kirn. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? , 2001, Gene Therapy.
[33] D. Carbone,et al. VEGF as a mediator of tumor-associated immunodeficiency , 2001, Immunologic research.
[34] M. Gulley,et al. Erratum: A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer (Clinical Cancer Research (2000) 6 (798-806)) , 2000 .
[35] D. Carbone,et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. , 1998, Blood.